International union of pharmacology - XXXVII. Nomenclature for leukotriene and lipoxin receptors

被引:232
作者
Brink, C
Dahlen, SE
Drazen, J
Evans, JF
Hay, DWP
Nicosia, S
Serhan, CN
Shimizu, T
Yokomizo, T
机构
[1] Hop Broussais, CNRS, UMR 7131, F-75014 Paris, France
[2] Karolinska Inst, Natl Inst Environm Med, Unit Expt Asthma & Allergy, Stockholm, Sweden
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Expt Therapeut & Reperfus Injury,Dept Anesthe, Boston, MA USA
[4] Merck & Co Inc, Dept Pharmacol, West Point, PA USA
[5] GlaxoSmithKline, King Of Prussia, PA USA
[6] Div Mol Pharmacol, Milan, Italy
[7] Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Tokyo 113, Japan
关键词
D O I
10.1124/pr.55.1.8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The leukotrienes and lipoxins are biologically active metabolites derived from arachidonic acid. Their diverse and potent actions are associated with specific receptors. Recent molecular techniques have established the nucleotide and amino acid sequences and confirmed the evidence that suggested the existence of different G-protein-coupled receptors for these lipid mediators. The nomenclature for these receptors has now been established for the leukotrienes. BLT receptors are activated by leukotriene B-4 and related hydroxyacids and this class of receptors can be subdivided into BLT1 and BLT2. The cysteinyl-leukotrienes (LT) activate another group called CysLT receptors, which are referred to as CysLT(1) and CysLT(2). A provisional nomenclature for the lipoxin receptor has also been proposed. LXA(4) and LXB4 activate the ALX receptor and LXB4 may also activate another putative receptor. However this latter receptor has not been cloned. The aim of this review is to provide the molecular evidence as well as the properties and significance of the leukotriene and lipoxin receptors, which has lead to the present nomenclature.
引用
收藏
页码:195 / 227
页数:33
相关论文
共 379 条
[1]   Leukotriene D4-induced activation of smooth-muscle cells from human bronchi is partly Ca2+-independent [J].
Accomazzo, MR ;
Rovati, GE ;
Viganò, T ;
Hernandez, A ;
Bonazzi, A ;
Bolla, M ;
Fumagalli, F ;
Viappiani, S ;
Galbiati, E ;
Ravasi, S ;
Albertoni, C ;
Di Luca, M ;
Caputi, A ;
Zannini, P ;
Chiesa, G ;
Villa, AM ;
Doglia, SM ;
Folco, G ;
Nicosia, S .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (01) :266-272
[2]   AIRWAY RESPONSIVENESS TO LEUKOTRIENE-C4 AND LEUKOTRIENE-D4 AND TO METHACHOLINE IN PATIENTS WITH ASTHMA AND NORMAL CONTROLS [J].
ADELROTH, E ;
MORRIS, MM ;
HARGREAVE, FE ;
OBYRNE, PM .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (08) :480-484
[3]   BIOCHEMICAL AND PHARMACOLOGICAL CHARACTERIZATION OF THE BINDING OF THE SELECTIVE PEPTIDE-LEUKOTRIENE ANTAGONIST, H-3-ICI 198,615, TO LEUKOTRIENE-D4 RECEPTORS IN GUINEA-PIG LUNG MEMBRANES [J].
AHARONY, D ;
FALCONE, RC ;
YEE, YK ;
HESP, B ;
GILES, RE ;
KRELL, RD .
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1988, 524 :162-180
[4]  
AHARONY D, 1989, J PHARMACOL EXP THER, V248, P581
[5]   Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells [J].
Akbar, GKM ;
Dasari, VR ;
Webb, TE ;
Ayyanathan, K ;
Pillarisetti, K ;
Sandhu, AK ;
Athwal, RS ;
Daniel, JL ;
Ashby, B ;
Barnard, EA ;
Kunapuli, SP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (31) :18363-18367
[6]   EFFECT OF INHALED LEUKOTRIENE-C4 ON CARDIOPULMONARY FUNCTION [J].
ALBAZZAZ, MK ;
PATEL, KR ;
SHAKIR, S ;
DARGIE, HJ ;
REID, JM .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1989, 139 (01) :188-193
[7]   Differential leukotriene constrictor responses in human atherosclerotic coronary arteries [J].
Allen, S ;
Dashwood, M ;
Morrison, K ;
Yacoub, M .
CIRCULATION, 1998, 97 (24) :2406-2413
[8]   PREFERENTIAL VASOCONSTRICTION TO CYSTEINYL LEUKOTRIENES IN THE HUMAN SAPHENOUS-VEIN COMPARED WITH THE INTERNAL MAMMARY ARTERY - IMPLICATIONS FOR GRAFT PERFORMANCE [J].
ALLEN, SP ;
CHESTER, AH ;
DASHWOOD, MR ;
TADJKARIMI, S ;
PIPER, PJ ;
YACOUB, MH .
CIRCULATION, 1994, 90 (01) :515-524
[9]  
ALLEN SP, 1993, CARDIOSCIENCE, V4, P47
[10]  
ALLEN SP, 1992, BRIT J CLIN PHARMACO, V34, P409